Methotrexate Update
I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.
News
EULAR 2018 - Day 3 Report
Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well.
EULAR 2018 - Podcast from Day 3
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
High Biologic Blood Levels Increases the Risk of Infections in RA
A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs. While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.
The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)
We're crazy busy at EULAR all week. Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam. You can find these on iTunes, SoundCloud or Stitcher.
Changing my Mind at EULAR
Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.
Update on Osteoporosis
This session was an update on the management of osteoporosis given by Professor Christian Roux from France.
Increased Risk of Infection in Psoriasis and Psoriatic Arthritis
As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival and comorbidities in PsA and PSO.
EULAR 2018 - Day 2 Report
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
EULAR 2018 - Podcast from Day 1 & 2
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Biosimilar Data at #EULAR2018
Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.
